Fucoidan and Lung Function: Value in Viral Infection

Compromised lung function is a feature of both infection driven and non-infective pathologies. Viral infections-including the current pandemic strain SARS-CoV-2-that affect lung function can cause both acute and long-term chronic damage. SARS-CoV-2 infection suppresses innate immunity and promotes a...

Full description

Saved in:
Bibliographic Details
Published in:Marine drugs 2020-12, Vol.19 (1), p.4
Main Authors: Fitton, J Helen, Park, Ah Young, Karpiniec, Samuel S, Stringer, Damien N
Format: Article
Language:English
Subjects:
Animals
corona
COVID-19 - immunology
COVID-19 Drug Treatment
fibrosis
fucoidan
Humans
influenza
lung
Lung - drug effects
Lung - physiology
Lung Diseases - drug therapy
Polysaccharides - pharmacology
Polysaccharides - therapeutic use
respiratory
Review
SARS-CoV-2
Virus Diseases - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Compromised lung function is a feature of both infection driven and non-infective pathologies. Viral infections-including the current pandemic strain SARS-CoV-2-that affect lung function can cause both acute and long-term chronic damage. SARS-CoV-2 infection suppresses innate immunity and promotes an inflammatory response. Targeting these aspects of SARS-CoV-2 is important as the pandemic affects greater proportions of the population. In clinical and animal studies, fucoidans have been shown to increase innate immunity and decrease inflammation. In addition, dietary fucoidan has been shown to attenuate pulmonary damage in a model of acute viral infection. Direct inhibition of SARS-CoV-2 in vitro has been described, but is not universal. This short review summarizes the current research on fucoidan with regard to viral lung infections and lung damage.
ISSN:1660-3397
1660-3397
DOI:10.3390/md19010004